ATE302850T1 - Apoptose-proteasen 3 und 4, ähnlich dem umwandlungsenzym für interleukin-1beta - Google Patents

Apoptose-proteasen 3 und 4, ähnlich dem umwandlungsenzym für interleukin-1beta

Info

Publication number: ATE302850T1
Authority: AT; Austria
Prior art keywords: polypeptides; interleukin; 1beta; similar; polypeptide
Prior art date: 1994-11-01

Application number

AT95922997T

Other languages

English (en)

Inventor

Wei Wu He

Craig A Rosen

Peter L Hudson

Gregg A Hastings

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-01

Filing date

1995-06-06

Publication date

2005-09-15

1995-06-06 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2005-09-15 Application granted granted Critical

2005-09-15 Publication of ATE302850T1 publication Critical patent/ATE302850T1/de

Links

230000006907 apoptotic process Effects 0.000 title abstract 2
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 title 1
102000004190 Enzymes Human genes 0.000 title 1
108090000790 Enzymes Proteins 0.000 title 1
102000003777 Interleukin-1 beta Human genes 0.000 title 1
108090000193 Interleukin-1 beta Proteins 0.000 title 1
102000035195 Peptidases Human genes 0.000 title 1
108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
238000006243 chemical reaction Methods 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 7
108090000765 processed proteins & peptides Proteins 0.000 abstract 7
102000004196 processed proteins & peptides Human genes 0.000 abstract 7
239000005557 antagonist Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
108020004414 DNA Proteins 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
101000715398 Homo sapiens Caspase-1 Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000003443 antiviral agent Substances 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000035772 mutation Effects 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)

AT95922997T 1994-11-01 1995-06-06 Apoptose-proteasen 3 und 4, ähnlich dem umwandlungsenzym für interleukin-1beta ATE302850T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/334,251 US6538121B1 (en)	1994-11-01	1994-11-01	Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
PCT/US1995/007235 WO1996013603A1 (en)	1994-11-01	1995-06-06	INTERLEUKIN-1 β CONVERTING ENZYME LIKE APOPTOSIS PROTEASE-3 AND 4

Publications (1)

Publication Number	Publication Date
ATE302850T1 true ATE302850T1 (de)	2005-09-15

Family

ID=23306335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95922997T ATE302850T1 (de)	1994-11-01	1995-06-06	Apoptose-proteasen 3 und 4, ähnlich dem umwandlungsenzym für interleukin-1beta

Country Status (8)

Country	Link
US (5)	US6538121B1 (de)
EP (1)	EP0792370B1 (de)
JP (2)	JP3675828B2 (de)
AT (1)	ATE302850T1 (de)
AU (1)	AU2768895A (de)
DE (1)	DE69534402T2 (de)
ES (1)	ES2247591T3 (de)
WO (1)	WO1996013603A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6538121B1 (en) *	1994-11-01	2003-03-25	Human Genome Sciences, Inc.	Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US6835555B1 (en) *	1994-11-01	2004-12-28	Human Genome Sciences, Inc.	Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
IL114615A0 (en)	1995-07-16	1995-11-27	Yeda Res & Dev	Modulators of the function of fas receptors and other proteins
US7097972B1 (en) *	1995-02-13	2006-08-29	Regents Of The University Of Michigan	Method and composition for regulating apoptosis
CA2218679A1 (en) *	1995-04-21	1996-10-24	Merck & Co., Inc.	Apopain
US6399327B1 (en)	1995-07-16	2002-06-04	Yeda Research And Development Co. Ltd.	Modulators of the function of FAS receptors and other proteins
ATE213773T1 (de) *	1995-11-03	2002-03-15	Vertex Pharma	In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür
US6462175B1 (en) *	1995-11-13	2002-10-08	Thomas Jefferson University	Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use
EP0842665A3 (de) *	1996-11-14	2002-12-18	Smithkline Beecham Corporation	Interleukin-1-beta-konvertierendes-Enzym-ähnliche Apoptosisproteasen und ihre Agonisten
US6432628B1 (en)	1997-08-26	2002-08-13	Thomas Jefferson University	Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
US6340740B1 (en)	1997-08-26	2002-01-22	Thomas Jefferson University	Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
WO2000004169A1 (en) *	1998-07-17	2000-01-27	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	New caspase homologue
AU2001288969A1 (en) *	2000-09-11	2002-03-26	Isis Pharmaceuticals, Inc.	Antisense modulation of caspase 7 expression
US20030199000A1 (en) *	2001-08-20	2003-10-23	Valkirs Gunars E.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040219509A1 (en) *	2001-08-20	2004-11-04	Biosite, Inc.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) *	2001-08-20	2004-10-21	Biosite Incorporated	Diagnostic markers of stroke and cerebral injury and methods of use thereof
DE60233949D1 (de) *	2001-08-20	2009-11-19	Biosite Inc	Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
US8658773B2 (en)	2011-05-02	2014-02-25	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2006035445A2 (en) *	2004-09-29	2006-04-06	Insight Biopharmaceuticals Ltd.	Methods of treating pathologies associated with oxidative stress
ES3000111T3 (en)	2009-02-13	2025-02-27	Immunomedics Inc	Intermediates for preparing conjugates with an intracellularly-cleavable linkage
US20160095939A1 (en)	2014-10-07	2016-04-07	Immunomedics, Inc.	Neoadjuvant use of antibody-drug conjugates
EP2478110B1 (de)	2009-09-16	2016-01-06	Immunomedics, Inc.	Klasse-i-anti-cea-antikörper und verwendungen davon
ES2978177T3 (es)	2009-12-02	2024-09-06	Immunomedics Inc	Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
CN104379169A (zh)	2012-08-14	2015-02-25	Ibc药品公司	用于治疗疾病的t-细胞重定向双特异性抗体
WO2017004144A1 (en)	2015-07-01	2017-01-05	Immunomedics, Inc.	Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh)	2012-12-13	2018-03-06	免疫医疗公司	功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
JP6447933B2 (ja)	2014-02-21	2019-01-09	アイビーシーファーマスーティカルズ，インコーポレイテッド	Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en)	2014-02-25	2015-09-03	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
EP3160504B1 (de)	2014-06-24	2020-09-16	Immunomedics, Inc.	Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
AU2016252771B2 (en)	2015-04-22	2021-12-16	Immunomedics, Inc.	Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP6980980B2 (ja)	2015-06-25	2021-12-15	イミューノメディクス、インコーポレイテッドImmunomedics, Inc.	抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
WO2019032628A1 (en)	2017-08-07	2019-02-14	The Regents Of The University Of California	GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
US10960071B2 (en)	2017-08-07	2021-03-30	The Regents Of The University Of California	Platform for generating safe cell therapeutics
WO2022239720A1 (ja)	2021-05-10	2022-11-17	公益財団法人川崎市産業振興財団	抗原への結合親和性を低減させた抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5260203A (en) *	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
EP0533226A3 (en)	1991-08-16	1993-08-18	Merck & Co. Inc.	Novel chromophore containing compounds
US5552536A (en) *	1994-04-08	1996-09-03	Merck Frosst Canada, Inc.	DNA encoding precursor of interleukin-1 beta converting enzyme - related cysteine proteinase III (ice rel-III)
US6538121B1 (en) *	1994-11-01	2003-03-25	Human Genome Sciences, Inc.	Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US6835555B1 (en) *	1994-11-01	2004-12-28	Human Genome Sciences, Inc.	Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
CA2218679A1 (en) *	1995-04-21	1996-10-24	Merck & Co., Inc.	Apopain

1994
- 1994-11-01 US US08/334,251 patent/US6538121B1/en not_active Expired - Lifetime
1995
- 1995-06-05 US US08/462,969 patent/US6087150A/en not_active Expired - Lifetime
- 1995-06-06 DE DE69534402T patent/DE69534402T2/de not_active Expired - Fee Related
- 1995-06-06 AT AT95922997T patent/ATE302850T1/de not_active IP Right Cessation
- 1995-06-06 WO PCT/US1995/007235 patent/WO1996013603A1/en not_active Ceased
- 1995-06-06 ES ES95922997T patent/ES2247591T3/es not_active Expired - Lifetime
- 1995-06-06 AU AU27688/95A patent/AU2768895A/en not_active Abandoned
- 1995-06-06 JP JP51452796A patent/JP3675828B2/ja not_active Expired - Fee Related
- 1995-06-06 EP EP95922997A patent/EP0792370B1/de not_active Expired - Lifetime
1998
- 1998-07-28 US US09/124,934 patent/US6495519B1/en not_active Expired - Lifetime
2001
- 2001-07-02 US US09/895,263 patent/US6733981B2/en not_active Expired - Fee Related
2002
- 2002-04-23 JP JP2002121377A patent/JP2003009889A/ja not_active Withdrawn
2008
- 2008-08-25 US US12/197,977 patent/US20090142329A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6087150A (en)	2000-07-11
DE69534402D1 (de)	2005-09-29
EP0792370A4 (de)	1997-10-22
EP0792370A1 (de)	1997-09-03
US6733981B2 (en)	2004-05-11
JPH11503901A (ja)	1999-04-06
AU2768895A (en)	1996-05-23
WO1996013603A1 (en)	1996-05-09
US20020076793A1 (en)	2002-06-20
DE69534402T2 (de)	2006-06-29
US20090142329A1 (en)	2009-06-04
US6495519B1 (en)	2002-12-17
JP3675828B2 (ja)	2005-07-27
ES2247591T3 (es)	2006-03-01
US6538121B1 (en)	2003-03-25
EP0792370B1 (de)	2005-08-24
JP2003009889A (ja)	2003-01-14

Legal Events

Date

Code

Title

Description

2006-05-15

UEP

Publication of translation of european patent specification

Ref document number: 0792370

Country of ref document: EP

2010-03-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE302850T1 (de)	2005-09-15	Apoptose-proteasen 3 und 4, ähnlich dem umwandlungsenzym für interleukin-1beta
HUP0103758A2 (hu)	2002-01-28	Neurotróf faktorok
DK1295944T3 (da)	2007-09-17	GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
EP0814158A3 (de)	1999-11-24	Abweichende Form des menschlichen C3a Rezeptor; diagnostzische und therapeutische Verwendungen
WO1998039446A3 (en)	1998-12-23	70 human secreted proteins
WO1998039448A3 (en)	1998-11-26	186 human secreted proteins
HUP0200064A2 (en)	2002-05-29	A method for the high level expression of active lymphotoxin-betha receptor immunoglobulin chimeric proteins and their purification
WO1998031818A3 (en)	1998-11-26	Tace-like and matrilysin-like polypeptides
DE3586189D1 (de)	1992-07-16	Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
EP1361229A3 (de)	2004-02-18	Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
NZ279963A (en)	1998-10-28	Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
WO1998045712A3 (en)	1998-12-03	20 human secreted proteins
WO2001036432A3 (en)	2002-05-10	18 human secreted proteins
WO2001032910A3 (en)	2002-01-24	27 human secreted proteins
DK1015477T3 (da)	2011-02-07	32 humane sekreterede proteiner
WO2001012776A3 (en)	2001-08-30	18 human secreted proteins
WO2001034768A3 (en)	2002-01-24	15 human secreted proteins
DE69533627D1 (en)	2004-11-11	Humanes chemokin beta-13
WO2000017222A8 (en)	2000-07-06	31 human secreted proteins
WO2000077026A8 (en)	2001-03-29	49 human secreted proteins
EP0192175A3 (de)	1988-01-20	Polypeptide des Rhinovirusstammes HRV2 sowie die hierfür codierenden DNA-Moleküle
WO2000063230A3 (en)	2001-02-08	49 human secreted proteins
EP0261403A3 (de)	1988-04-13	Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
WO2001012775A8 (en)	2001-12-06	25 human secreted proteins
WO2000061624A8 (en)	2001-03-08	48 human secreted proteins